Mendel Kaelen

Founder and CEO of Wavepaths, Neuroscientist

Data updated

Papers

38 publications

Trials

0 clinical trials

Links

Website

Research Footprint

Mendel Kaelen appears in 38 tracked papers (2013–2026), most studied alongside LSD, Psilocybin and Ayahuasca, across Depressive Disorders, Neuroimaging & Brain Measures and Healthy Volunteers.

Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).

Frequent co-authors: Robin Carhart-Harris, David Nutt and Leor Roseman.

Background & Research

Mendel Kaelen is a neuroscientist known for his foundational research at Imperial College London on the synergy between music and psychedelics. His work demonstrated how music-evoked emotion is enhanced by psychedelics and plays a central role in therapeutic breakthrough. He founded Wavepaths to translate these scientific insights into personalized music environments for healthcare.

Key Impact

The foremost researcher on the critical role of music in facilitating therapeutic outcomes in psychedelic medicine.

38

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

49 collaborators· click a node to visit their profile

Full network →

Compounds

LSDPsilocybinAyahuascaPlaceboMDMAMescaline

Topics

Depressive DisordersNeuroimaging & Brain MeasuresHealthy VolunteersSet & SettingTreatment-Resistant Depression (TRD)Anxiety DisordersPersonality & Trait FactorsSubstance Use Disorders (SUD)Palliative & End-of-Life DistressMajor Depressive Disorder (MDD)Obsessive-Compulsive Disorder (OCD)SchizophreniaEquity and EthicsPTSDAdolescentsAlcohol Use Disorder (AUD)Tobacco/Nicotine Use Disorder (TUD)Headache Disorders (Cluster & Migraine)Safety & Risk ManagementChronic PainBipolar DisorderInterpersonal Functioning & Social Connectedness

Top Collaborators

Affiliations

Institutions, companies, and organisations Mendel Kaelen is associated with.

Imperial College London

academic

The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).

View stakeholder →

Wavepaths

Adaptive digital music platform for psychedelic and consciousness-altering therapy contexts, enabling immersive, session-responsive media experiences.

View stakeholder →